Research analysts covering Altamira Therapeutics.
Recent press releases and 8-K filings for CYTOF.
Altamira Therapeutics Reports First Half 2025 Financial Results and Business Update
CYTOF
Earnings
Guidance Update
New Projects/Investments
- Altamira Therapeutics reported a net loss of $1.5 million for the first half of 2025, a 64.6% decrease from $4.3 million in the first half of 2024, with the operating loss decreasing by 32.9% to $2.6 million. However, cash and cash equivalents significantly decreased to $4 thousand as of June 30, 2025, from $1.0 million at year-end 2024.
- The company is advancing plans for a partial spin-off of its RNA delivery business, operated through its Swiss subsidiary Altamira Therapeutics AG (ATAG), to involve private equity investors for funding.
- The Board of Directors considers it feasible to generate $2.8 million to $3.5 million in funding within 12 months from August 27, 2025, but notes that these plans have not yet been fully realized, raising substantial doubt about the company's ability to continue as a going concern.
- In 2025, Altamira secured two new collaboration partners for the evaluation of its xPhore RNA delivery platform, including for circular RNA (CycloPhore) and radiopharmaceutical applications.
Aug 29, 2025, 11:41 AM
Quarterly earnings call transcripts for Altamira Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more